Bulk Inquiry
LDN 193189 hydrochloride
- Parent CAS: 1062368-24-4
- Soluble in water and DMSO
- MF: C25H22N6.2HCl
- MW: 479.4
Description
LDN-193189 is a highly potent BMP signaling inhibitor that selectively targets BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM respectively. LDN-193189 effectively blocks BMP pathway signaling and downstream SMAD phosphorylation.
LDN193189 is widely used in stem cell differentiation research and demonstrates significant in vivo bioactivity with therapeutic potential in treating fibrodysplasia ossificans progressiva (FOP), preventing abnormal ectopic bone growth, and in studies on non-small cell lung cancer (NSCLC).
LDN193189 hydrochloride is the preferred salt form, offering superior solubility in aqueous solutions and DMSO compared to the free base, making it easier to prepare stock solutions for cell culture applications.
Key Features
- Potent ALK2 and ALK3 inhibitor
- IC50: 5 nM for ALK2 and 30 nM for ALK3
- Blocks BMP pathway signaling and SMAD phosphorylation
- Widely used in stem cell differentiation studies
- Preferred water-soluble hydrochloride salt form with improved solubility in DMSO
- Demonstrates significant in vivo bioactivity
Applications
- Stem cell differentiation research
- BMP and TGF-β signaling studies
- ALK2 and ALK3 receptor biology
- Fibrodysplasia ossificans progressiva (FOP) research
- Ectopic ossification studies
- Non-small cell lung cancer (NSCLC) research
Promotion: LDN193189 hydrochloride is also included in the following inhibitor sets:
| Stem Cell LSB inhibitor Set (Axon 5004) |
| Stem Cell LSC inhibitor Set (Axon 5005) |
| Stem Cell 5i inhibitor Set (Axon 5007) |
Prime Source Information:
The molecule of LDN-193189 contains multiple basic nitrogens, which can form 1–4 eq HCl salts. Axon Medchem supplies high-quality LDN-193189 hydrochloride with the accurate salt form verified by microanalysis and specified on the certificate of analysis (COA) for every batch.
More Information
| Parent CAS No. | 1062368-24-4 |
|---|---|
| Chemical Name | 4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline hydrochloride |
| SMILES | C1(C2C=CC(N3CCNCC3)=CC=2)=CN2N=CC(C3C4=CC=CC=C4N=CC=3)=C2N=C1.Cl.Cl |
| MFCD | MFCD20926415 |
| InChi | InChI=1S/C25H22N6.2ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30;;/h1-10,15-17,26H,11-14H2;2*1H |
| InChiKey | CMQXLLAILGGLRV-UHFFFAOYSA-N |
| CID | 25195294 |
| Short Description | BMP inhibitor |
References
- EM Langenfeld and J Langenfeld. Bone Morphogenetic Protein-2 Stimulates Angiogenesis in Developing Tumors. Mol. Cancer Res. 2004, 2, 141–149.
- PB Yu et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat. Med. 2008, 14, 1363-1369.
- GD Cuny et al. Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4388–4392.
- PB Yu et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 2008, 4, 33-41.
- List of publications using LDN 193189 dihydrochloride (Axon 1509) purchased from Axon Medchem
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1387 | SD 208 |
From $55.00 |
| 1421 | A 83-01 |
From $77.00 |
| 1491 | LY 2157299 |
From $66.00 |
| 1661 | SB 431542 |
From $77.00 |
| 1708 | Dorsomorphin |
From $71.50 |
| 1744 | A 77-01 |
From $88.00 |
| 1832 | GW 788388 |
From $55.00 |
| 2150 | Dorsomorphin dihydrochloride |
From $71.50 |
| 2189 | K 02288 |
From $99.00 |
| 2197 | SB 505124 |
From $104.50 |
| 2201 | LDN 212854 trihydrochloride |
From $121.00 |
| 2426 | SMURF1 inhibitor A01 |
From $126.50 |
| 2605 | Selexipag |
From $99.00 |
| 2903 | SJ000291942 |
From $104.50 |
| 3552 | LDN 212854 |
From $121.00 |
| 3914 | CDD-1653 |
From $121.00 |
| 4165 | SB4 |
From $88.00 |
| 4387 | DMH-1 |
From $132.00 |
| 5004 | Stem Cell LSB inhibitor Set |
From $99.00 |
| 5005 | Stem Cell LSC inhibitor Set |
From $143.00 |
| 5007 | Stem Cell 5i inhibitor Set |
From $220.00 |
